A study led by Helena Jernberg Wiklund, Uppsala University/SciLifeLab, shows how the protein EZH2 affects the development of multiple myeloma, and that inhibition of EZH2 could be used as a new strategy to treat the disease. The cancer form multiple myeloma is today incurable and it has been challenging to improve therapy. The study was published in Oncotarget.

Read full press release